Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 1 to 20 of 34

1.

Primary lateral sclerosis

MedGen UID:
57591
Concept ID:
C0154682
Disease or Syndrome
2.

Sclerosis

hardening of the tissue [from CHV]

MedGen UID:
48587
Concept ID:
C0036429
Pathologic Function
3.

Amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease involving both upper motor neurons (UMN) and lower motor neurons (LMN). UMN signs include hyperreflexia, extensor plantar response, increased muscle tone, and weakness in a topographic representation. LMN signs include weakness, muscle wasting, hyporeflexia, muscle cramps, and fasciculations. Initial presentation varies. Affected individuals typically present with either asymmetric focal weakness of the extremities (stumbling or poor handgrip) or bulbar findings (dysarthria, dysphagia). Other findings may include muscle fasciculations, muscle cramps, and labile affect, but not necessarily mood. Regardless of initial symptoms, atrophy and weakness eventually affect other muscles. The mean age of onset is 56 years in individuals with no known family history and 46 years in individuals with more than one affected family member (familial ALS or FALS). Average disease duration is about three years, but it can vary significantly. Death usually results from compromise of the respiratory muscles. [from GeneReviews]

MedGen UID:
274
Concept ID:
C0002736
Disease or Syndrome
4.

Amyotrophic lateral sclerosis

MedGen UID:
506059
Concept ID:
CN006437
Finding
5.

Sodium Phenylbutyrate

MedGen UID:
450033
Concept ID:
CN077558
Pharmacologic Substance
6.

Sodium phenylbutyrate

A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called differentiating agents. [from NCI_NCI-GLOSS]

MedGen UID:
152407
Concept ID:
C0718066
Pharmacologic Substance
7.

Pelizaeus-Merzbacher disease

PLP1-related disorders of central nervous system myelin formation include a range of phenotypes from Pelizaeus-Merzbacher disease (PMD) to spastic paraplegia 2 (SPG2). PMD typically manifests in infancy or early childhood with nystagmus, hypotonia, and cognitive impairment; the findings progress to severe spasticity and ataxia. Life span is shortened. SPG2 manifests as spastic paraparesis with or without CNS involvement and usually normal life span. Intrafamilial variation of phenotypes can be observed, but the signs are usually fairly consistent within families. Female carriers may manifest mild to moderate signs of the disease. [from GeneReviews]

MedGen UID:
61440
Concept ID:
C0205711
Disease or Syndrome
8.

Course of illness

Stages or progression of physical or mental disorders. Compare PROGNOSIS. [from PSY]

MedGen UID:
116631
Concept ID:
C0242656
Pathologic Function
9.

Lymphoma

Lymphoma is a cancer of a part of the immune system called the lymphatic system. There are many types of lymphoma. One type is called Hodgkin disease. The rest are called non-Hodgkin lymphoma. . Non-Hodgkin lymphomas begin when a type of white blood cell, called a T cell or B cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors can't determine why a person gets non-Hodgkin lymphoma. . Non-Hodgkin lymphoma can cause many symptoms, such as : -Swollen, painless lymph nodes in the neck, armpits or groin. -Unexplained weight loss . -Fever . -Soaking night sweats . -Coughing, trouble breathing or chest pain . -Weakness and tiredness that don't go away . -Pain, swelling or a feeling of fullness in the abdomen . Your doctor will perform an exam and lab tests to determine if you have lymphoma. NIH: National Cancer Institute.  [from MedlinePlus]

MedGen UID:
44223
Concept ID:
C0024299
Neoplastic Process
10.

Curcumin stain

A phytopolylphenol pigment isolated from the plant Curcuma longa, commonly known as tumeric, with a variety of pharmacologic properties. Curcumin blocks the formation of reactive-oxygen species, possesses anti-inflammatory properties as a result of inhibition of cyclooxygenases (COX) and other enzymes involved in inflammation; and disrupts cell signal transduction by various mechanisms including inhibition of protein kinase C. These effects may play a role in the agent's observed antineoplastic properties, which include inhibition of tumor cell proliferation and suppression of chemically induced carcinogenesis and tumor growth in animal models of cancer. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43115&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43115&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C401" NCI Thesaurus) [from PDQ]

MedGen UID:
1184
Concept ID:
C0010467
Pharmacologic Substance
11.

Lymphoma

A cancer originating in lymphocytes and presenting as a solid tumor of lymhpoid cells. [from HPO]

MedGen UID:
505322
Concept ID:
CN002422
Finding
12.

Histone deacetylase inhibitor

A substance that causes a chemical change that stops tumor cells from dividing. HDAC inhibitors are being studied in the treatment of cancer. [from NCI]

MedGen UID:
268200
Concept ID:
C1512474
Pharmacologic Substance
13.

Caspase Activation

Caspase Activation involves induction of the activity of intracellular cysteine endopeptidase family members kept inactive by mitochondrial surface proteins (BcL-2 Family) and involved in initial signaling and downstream proteolytic cleavages (at P1 aspartic acids) in inflammation and apoptotic cell death when signals block BcL-2 function and activators initiate caspase cascades. [from NCI]

MedGen UID:
223891
Concept ID:
C1159825
Molecular Function
14.

TDP-43 Proteinopathies

Diseases characterized by the presence of abnormally phosphorylated, ubiquitinated, and cleaved DNA-binding protein TDP-43 in affected brain and spinal cord. Inclusions of the pathologic protein in neurons and glia, without the presence of AMYLOID, is the major feature of these conditions, thus making these proteinopathies distinct from most other neurogenerative disorders in which protein misfolding leads to brain amyloidosis. Both frontotemporal lobar degeneration and AMYOTROPHIC LATERAL SCLEROSIS exhibit this common method of pathogenesis and thus they may represent two extremes of a continuous clinicopathological spectrum of one disease. [from MeSH]

MedGen UID:
439336
Concept ID:
C2718017
Disease or Syndrome
15.

Proteostasis Deficiencies

Disorders caused by imbalances in the protein homeostasis network - synthesis, folding, and transport of proteins; post-translational modifications; and degradation or clearance of misfolded proteins. [from MeSH]

MedGen UID:
403490
Concept ID:
C2718000
Cell or Molecular Dysfunction
16.

Caspase Inhibitors

Endogenous and exogenous compounds and that either inhibit CASPASES or prevent their activation. [from MeSH]

MedGen UID:
273884
Concept ID:
C1516312
Pharmacologic Substance
17.

Molecular Mechanisms of Pharmacological Action

Pharmacological activities at the molecular level of DRUGS and other exogenous compounds that are used to treat DISEASES and affect normal BIOCHEMISTRY. [from MeSH]

MedGen UID:
226255
Concept ID:
C1258062
Molecular Function
18.

Disease Attributes

Clinical characteristics of disease or illness. [from MeSH]

MedGen UID:
199876
Concept ID:
C0752357
Disease or Syndrome
19.

Neurodegenerative Disorders

Neurodegenerative disorders, such as Hunter syndrome, or sensory motor neuropathies, such as Friedreich ataxia and Charcot-Marie-Tooth syndrome. [from LNC]

MedGen UID:
101195
Concept ID:
C0524851
Disease or Syndrome
20.

phenol

An antiseptic and disinfectant aromatic alcohol. [from MeSH]

MedGen UID:
74524
Concept ID:
C0070570
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...